Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

Inclusion Criteria:

• All participants must have a diagnosis of plaque psoriasis (with or withoutpsoriatic arthritis) for at least 6 months before first administration of studyintervention

• All participants must meet the following disease severity criteria at screening andat baseline: (a) Overall Investigator's Global Assessment (IGA) 3 (moderate) plaquepsoriasis; (b) Body Surface Area (BSA) 2-15 percent (%) with at least 1 plaqueoutside of special sites; (c) Involvement of at least 1 special site with at leastmoderate severity. Qualifying sites include scalp with scalp-specific IGA greaterthan or equal to (>=) 3, face with facial psoriasis IGA >=3, intertriginous withintertriginous psoriasis IGA >=3, or genital with static physician global assessmentof genitalia (sPGA-G) >=3

• All participants be inadequately controlled with or intolerant of at least 1 priortopical therapy (including, but not limited to, corticosteroids, retinoids, vitaminD, or vitamin D/steroid and retinoid/steroid combinations, tacrolimus, pimecrolimus,anthralin/dithranol, coal tar preparations, tapinarof, roflumilast, etcetera) forthe treatment of psoriasis at both screening

• All participants be a candidate for phototherapy or systemic treatment for psoriasis

Exclusion Criteria:

• Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular) atscreening or randomization

• Has current drug-induced psoriasis (for example, a new onset of psoriasis or anexacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)

• For participants with palmoplantar involvement, confounding diagnoses, including,but not limited, to palmoplantar pustulosis, eczematous dermatitis, contact/irritantdermatitis, acquired keratoderma, etcetera, should be confirmed and excluded

• Participants will not be eligible if they have ever received prior biologic (orbiosimilars of) for the treatment of psoriasis, psoriatic arthritis (PsA), or anyother indications that could impact the assessment of psoriasis. Prior biologics (orbiosimilars of) may include, but not limited to, tumor necrosis factor (TNF)-inhibitors (for example: adalimumab, etanercept, infliximab, or certolizumabor biosimilars), interleukin (IL)-17 inhibitors (for example: secukinumab,ixekizumab, brodalumab, or bimekizumab), and IL-12/23 inhibitors (for example:ustekinumab), or IL-23 inhibitor (for example: guselkumab, risankizumab ortildrakizumab)

• Has a history of chronic or recurrent infectious disease, including, but not limitedto, chronic renal infection, chronic chest infection (for example, bronchiectasis),recurrent urinary tract infection (recurrent pyelonephritis or chronic non-remittingcystitis), fungal infection (mucocutaneous candidiasis), or open, draining, orinfected skin wounds or ulcers